C-reactive protein and coronary artery disease: Influence of obesity, caloric restriction and weight loss

Journal of Nutritional Biochemistry

Volumn 13, Issue 6, 2002, Pages 316-321

  Heilbronn, Leonie K ^a   Clifton, Peter M ^a  

^a CSIRO   (Australia)

Author keywords

Adipose tissue; CRP; IL 6; Weight loss

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; C REACTIVE PROTEIN; DEXAMETHASONE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; NITRIC OXIDE; ONCOSTATIN M; TRIACYLGLYCEROL; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADIPOCYTE; ARTERY WALL; BODY MASS; CALORIC RESTRICTION; CHOLESTEROL BLOOD LEVEL; COMPLEMENT ACTIVATION; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; GENE CONTROL; HORMONE SUBSTITUTION; HUMAN; INSULIN RESISTANCE; MACROPHAGE; MONOCYTE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; WEIGHT REDUCTION;

EID: 0036095637     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-2863(02)00187-0     Document Type: Review

References (70)

1. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein
2. Interleukin-6-dependent and -independent regulation of the human C-reactive protein gene
3. Atherosclerosis - An inflammatory disease
4. Elevation of C-reactive protein in "active" coronary artery disease
5. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
6. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris, European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group
7. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies
8. Inflammation, Aspirin, and the risk of cardiovascular disease in apparently healthy men
9. C-reactive protein and coronary heart disease in western Turkey
10. Association of C-reactive protein with markers of prevalent atherosclerotic disease
11. C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis
12. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions
13. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels, Cholesterol and Recurrent Events (CARE) Investigators
14. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
15. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators
16. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study
17. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering
18. Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis
19. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas
20. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque
21. C-reactive protein-mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis
22. Complement and atherogenesis: Binding of CRP to degraded, nonoxidized LDL enhances complement activation
23. Atherogenic properties of enzymatically degraded LDL: Selective induction of MCP-1 and cytotoxic effects on human macrophages
24. Direct proinflammatory effect of C-reactive protein on human endothelial cells
25. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor
26. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: Relationship with age, sex, and hormone replacement treatment
27. C-reactive protein in population samples
28. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset
29. Chronic infections and coronary heart disease: Is there a link?
30. Elevated C-reactive protein in overweight and obese adults
31. C Reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study
32. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and Rural Health Promotion Project
33. C-reactive protein concentration in children: Relationship to adiposity and other cardiovascular risk factors
34. Associations of C-reactive protein with measures of obesity, insulin resistance and subclinical atherosclerosis in healthy, middle-aged women
35. Chronic subclinical inflammation as part of the insulin resistance syndrome. The insulin resistance atherosclerosis study (IRAS)
36. C-Reactive protein in healthy subjects, Associations with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue?
37. Elevated C-reactive protein: Another component of the atherothrombotic profile of abdominal obesity
38. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians
39. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo
40. Human subcutaneous adipose tissue releases IL-6 but not TNF-α in vivo
41. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: Depot difference and regulation by glucocorticoid
42. Interleukin-6 exacerbates early atherosclerosis in mice
43. Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: A possible role for interleukin-6
44. Complement-dependent acute-phase expression of C-reactive protein and serum amyloid P-component
45. Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice
46. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels
47. Sepsis-induced changes in in vivo insulin action in diabetic rats
48. Insulin resistance and inflammation in an evolutionary perspective: The contribution of cytokine genotype/phenotype to thriftiness
49. C-Reactive protein, interleukin-6 and risk of developing type 2 diabetes
50. The relation of markers of inflammation to the development of glucose disorders in the elderly: The Cardiovascular Health Study
51. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion
52. Body mass index, diabetes, and C-reactive protein among U.S. adults
53. Hormone replacement therapy and increased plasma concentration of C-reactive protein
54. Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women
55. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women
56. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women, Heart and Estrogen/progestin Replacement Study (HERS) Research Group
57. Weight loss and progression of early atherosclerosis in the carotid artery: A four-year controlled study of obese subjects
58. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women
59. Weight loss reduces C-reactive protein levels in obese postmenopausal women
60. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance
61. Elevated levels of interleukin-6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss
62. Tumor necrosis factor receptor (TNFR) 1, but not TNFR2, mediates tumor necrosis factor-alpha-induced interleukin-6 and RANTES in human airway smooth muscle cells: Role of p38 and p42/44 mitogen-activated protein kinases
63. Tumor necrosis factor-alpha induces interleukin-6 production and integrin ligand expression by distinct transduction pathways
64. Calorie restriction attenuates inflammatory responses to myocardial ischemia-reperfusion injury
65. Attenuated allergic responses to house dust mite antigen in feed-restricted rats
66. Caloric restriction as a mechanism mediating resistance to environmental disease
67. Serum levels of interleukin-6 and dehydroepiandrosterone sulphate in response to either fasting or a ketogenic diet in rheumatoid arthritis patients
68. Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells
69. Characterization of differentiation factor/leukaemia inhibitory factor effect on lipoprotein lipase activity and mRNA in 3T3-L1 adipocytes
70. Human breast adipocytes express interleukin-6 (IL-6) and its receptor system: Increased IL-6 production by beta-adrenergic activation and effects of IL-6 on adipocyte function